A combination trial of vaccine plus ipilimumab in metastatic castration-resistant prostate cancer patients: immune correlates

Ipilimumab alone or in combination with radiotherapy in metastatic castration-resistant prostate cancer: results from an open-label, multicenter phase I/II study

(2013) S. F. Slovin et al.   ANNALS OF ONCOLOGY

Tim-3 marks human natural killer cell maturation and suppresses cell-mediated cytotoxicity

(2012) L. C. Ndhlovu et al.   BLOOD

Tim-3 is an inducible human natural killer cell receptor that enhances interferon gamma production in response to galectin-9

(2012) M. K. Gleason et al.   BLOOD

Combined immunotherapy with granulocyte-macrophage colony-stimulating factor-transduced allogeneic prostate cancer cells and ipilimumab in patients with metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Alfons JM van den Eertwegh et al.   LANCET ONCOLOGY

Ipilimumab and a poxviral vaccine targeting prostate-specific antigen in metastatic castration-resistant prostate cancer: a phase 1 dose-escalation trial

(2012) Ravi A Madan et al.   LANCET ONCOLOGY

Multipeptide immune response to cancer vaccine IMA901 after single-dose cyclophosphamide associates with longer patient survival

(2012) Steffen Walter et al.   NATURE MEDICINE

Safety and Activity of Anti–PD-L1 Antibody in Patients with Advanced Cancer

(2012) Julie R. Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Safety, Activity, and Immune Correlates of Anti–PD-1 Antibody in Cancer

(2012) Suzanne L. Topalian et al.   NEW ENGLAND JOURNAL OF MEDICINE

Tim-3-Expressing CD4+ and CD8+ T Cells in Human Tuberculosis (TB) Exhibit Polarized Effector Memory Phenotypes and Stronger Anti-TB Effector Functions

(2012) Yueqin Qiu et al.   PLoS Pathogens

Immunologic biomarkers as correlates of clinical response to cancer immunotherapy

(2011) Mary L. Disis   CANCER IMMUNOLOGY IMMUNOTHERAPY

The ICOS/ICOSL Pathway Is Required for Optimal Antitumor Responses Mediated by Anti-CTLA-4 Therapy

(2011) T. Fu et al.   CANCER RESEARCH

Epitope spreading contributes to effective immunotherapy in metastatic melanoma patients

(2011) Nicola Hardwick et al.   Immunotherapy

Myeloid derived suppressor cells in human diseases

(2011) Tim F. Greten et al.   INTERNATIONAL IMMUNOPHARMACOLOGY

CD56brightCD16+ NK Cells: A Functional Intermediate Stage of NK Cell Differentiation

(2011) V. Beziat et al.   JOURNAL OF IMMUNOLOGY

Ipilimumab plus Dacarbazine for Previously Untreated Metastatic Melanoma

(2011) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Protective Effector Memory CD4 T Cells Depend on ICOS for Survival

(2011) Tamson V. Moore et al.   PLoS One

Single-institution experience with ipilimumab in advanced melanoma patients in the compassionate use setting

(2010) Geoffrey Y. Ku et al.   CANCER

Analysis of circulating regulatory T cells in patients with metastatic prostate cancer pre- versus post-vaccination

(2010) Matteo Vergati et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Preoperative CTLA-4 Blockade: Tolerability and Immune Monitoring in the Setting of a Presurgical Clinical Trial

(2010) B. C. Carthon et al.   CLINICAL CANCER RESEARCH

Overall Survival Analysis of a Phase II Randomized Controlled Trial of a Poxviral-Based PSA-Targeted Immunotherapy in Metastatic Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   JOURNAL OF CLINICAL ONCOLOGY

Improved Survival with Ipilimumab in Patients with Metastatic Melanoma

(2010) F. Stephen Hodi et al.   NEW ENGLAND JOURNAL OF MEDICINE

Sipuleucel-T Immunotherapy for Castration-Resistant Prostate Cancer

(2010) Philip W. Kantoff et al.   NEW ENGLAND JOURNAL OF MEDICINE

Cooperation of Tim-3 and PD-1 in CD8 T-cell exhaustion during chronic viral infection

(2010) H.-T. Jin et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Does PSADT After Radical Prostatectomy Correlate With Overall Survival?—A Report From the SEARCH Database Group

(2010) Anna E. Teeter et al.   UROLOGY

Immunologic and prognostic factors associated with overall survival employing a poxviral-based PSA vaccine in metastatic castrate-resistant prostate cancer

(2009) James L. Gulley et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Enhancing Cancer Vaccine Efficacy via Modulation of the Tumor Microenvironment

(2009) M. L. Disis   CLINICAL CANCER RESEARCH

Blockade of CTLA-4 on both effector and regulatory T cell compartments contributes to the antitumor activity of anti–CTLA-4 antibodies

(2009) Karl S. Peggs et al.   JOURNAL OF EXPERIMENTAL MEDICINE

Anti-CTLA-4 therapy results in higher CD4+ICOShiT cell frequency and IFN-γ levels in both nonmalignant and malignant prostate tissues

(2009) Hong Chen et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

Immunosuppressive CD14+HLA-DRlow/−monocytes in prostate cancer

(2009) Stanimir Vuk-Pavlović et al.   PROSTATE

Phenotypic Analysis of Prostate-Infiltrating Lymphocytes Reveals TH17 and Treg Skewing

(2008) K. S. Sfanos et al.   CLINICAL CANCER RESEARCH

CTLA-4 blockade increases IFN -producing CD4+ICOShi cells to shift the ratio of effector to regulatory T cells in cancer patients

(2008) C. I. Liakou et al.   PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA

CTLA-4 Control over Foxp3+ Regulatory T Cell Function

(2008) K. Wing et al.   SCIENCE